BRCA-Mutated Ovarian Cancer Archives

Foundation Medicine Expands Indication for FoundationOne CDx as a Companion Diagnostic for Lynparza

Foundation Medicine Inc. received approval from the U.S. Food and Drug Administration for FoundationOne CDx to be used as a companion diagnostic for Lynparza (olaparib) for first-line maintenance therapy in BRCA-mutated advanced ovarian cancer.

July 1, 2019/by Business Wire

AstraZeneca’s Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

Advanced pancreatic cancer, Analysts, Approvals, BRCA Gene, BRCA mutation, BRCA-Mutated Ovarian Cancer, European Commission, FDA/Regulatory, Future Blockbusters, Ovarian Cancer, PARP Inhibitors

Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission.

June 18, 2019/by Reuters Health